Based on this four-case series, we have designed a multi-institutional study to evaluate whether there is a rationale behind late and atypical radionecrosis after SRS in brain metastases among larger cohorts of HER2-positive breast cancer patients. This evidence concerns the gene ERBB2 and breast cancer.